Arrowhead Pharmaceuticals, Inc.

LSE:0HI3 Stock Report

Market Cap: US$2.6b

Arrowhead Pharmaceuticals Valuation

Is 0HI3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HI3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0HI3's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0HI3's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HI3?

Key metric: As 0HI3 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0HI3. This is calculated by dividing 0HI3's market cap by their current book value.
What is 0HI3's PB Ratio?
PB Ratio7.9x
BookUS$330.55m
Market CapUS$2.62b

Price to Book Ratio vs Peers

How does 0HI3's PB Ratio compare to its peers?

The above table shows the PB ratio for 0HI3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.7x
GNS Genus
2x37.7%UK£1.1b
OXB Oxford Biomedica
6.8x93.2%UK£447.8m
PRTC PureTech Health
1.6x-13.0%UK£396.5m
BVXP Bioventix
16.3xn/aUK£195.7m
0HI3 Arrowhead Pharmaceuticals
7.9x19.8%US$2.6b

Price-To-Book vs Peers: 0HI3 is expensive based on its Price-To-Book Ratio (7.9x) compared to the peer average (6.7x).

Price to Book Ratio vs Industry

How does 0HI3's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
0HI3 7.9xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0HI3 is expensive based on its Price-To-Book Ratio (7.9x) compared to the UK Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is 0HI3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HI3 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio7.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0HI3's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HI3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$23.53
US$45.69
+94.2%
38.2%US$71.00US$23.00n/a13
Nov ’25US$19.63
US$47.29
+140.9%
37.0%US$71.00US$20.00n/a14
Oct ’25US$18.76
US$47.29
+152.1%
37.0%US$71.00US$20.00n/a14
Sep ’25US$23.40
US$47.21
+101.8%
37.3%US$71.00US$19.00n/a14
Aug ’25US$27.25
US$50.29
+84.5%
33.2%US$74.00US$27.00n/a14
Jul ’25US$25.80
US$52.43
+103.2%
37.2%US$90.00US$27.00n/a14
Jun ’25US$22.78
US$53.77
+136.1%
36.2%US$90.00US$27.00n/a13
May ’25US$23.12
US$53.66
+132.1%
34.5%US$90.00US$28.00n/a14
Apr ’25US$28.95
US$55.15
+90.5%
33.3%US$90.00US$28.00n/a13
Mar ’25US$35.55
US$55.15
+55.1%
33.3%US$90.00US$28.00n/a13
Feb ’25US$32.13
US$55.46
+72.6%
36.0%US$90.00US$27.00n/a13
Jan ’25US$30.78
US$53.29
+73.1%
39.6%US$90.00US$24.00n/a14
Dec ’24US$22.08
US$55.08
+149.5%
36.5%US$90.00US$24.00n/a13
Nov ’24US$25.13
US$55.93
+122.6%
34.7%US$90.00US$26.00US$19.6314
Oct ’24US$27.32
US$56.71
+107.6%
33.9%US$90.00US$27.00US$18.7614
Sep ’24US$28.06
US$58.54
+108.6%
32.0%US$90.00US$27.00US$23.4013
Aug ’24US$33.99
US$62.15
+82.9%
28.1%US$90.00US$27.00US$27.2513
Jul ’24US$35.52
US$61.77
+73.9%
28.4%US$90.00US$27.00US$25.8013
Jun ’24US$34.80
US$62.07
+78.4%
28.0%US$90.00US$27.00US$22.7814
May ’24US$35.75
US$61.14
+71.0%
28.8%US$90.00US$27.00US$23.1214
Apr ’24US$25.32
US$61.00
+140.9%
33.2%US$90.00US$21.00US$28.9514
Mar ’24US$32.67
US$63.62
+94.7%
29.2%US$90.00US$21.00US$35.5513
Feb ’24US$35.05
US$65.38
+86.5%
29.0%US$90.00US$22.00US$32.1313
Jan ’24US$40.10
US$69.69
+73.8%
26.7%US$92.00US$31.00US$30.7813
Dec ’23US$32.20
US$71.23
+121.2%
29.4%US$110.00US$31.00US$22.0813
Nov ’23US$35.97
US$73.50
+104.3%
29.1%US$110.00US$32.00US$25.1312

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.35

7D

2.8%

1Y

-24.9%

Regeneron Pharmaceuticals

US$81.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$749.80

7D

1.3%

1Y

-7.7%